Literature DB >> 14514628

A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes.

Sangeeta Kashyap1, Renata Belfort, Amalia Gastaldelli, Thongchai Pratipanawatr, Rachele Berria, Wilailak Pratipanawatr, Mandeep Bajaj, Lawrence Mandarino, Ralph DeFronzo, Kenneth Cusi.   

Abstract

Acute elevations in free fatty acids (FFAs) stimulate insulin secretion, but prolonged lipid exposure impairs beta-cell function in both in vitro studies and in vivo animal studies. In humans data are limited to short-term (< or =48 h) lipid infusion studies and have led to conflicting results. We examined insulin secretion and action during a 4-day lipid infusion in healthy normal glucose tolerant subjects with (FH+ group, n = 13) and without (control subjects, n = 8) a family history of type 2 diabetes. Volunteers were admitted twice to the clinical research center and received, in random order, a lipid or saline infusion. On days 1 and 2, insulin and C-peptide concentration were measured as part of a metabolic profile after standardized mixed meals. Insulin secretion in response to glucose was assessed with a +125 mg/dl hyperglycemic clamp on day 3. On day 4, glucose turnover was measured with a euglycemic insulin clamp with [3-3H]glucose. Day-long plasma FFA concentrations with lipid infusion were increased within the physiological range, to levels seen in type 2 diabetes (approximately 500-800 micromol/l). Lipid infusion had strikingly opposite effects on insulin secretion in the two groups. After mixed meals, day-long plasma C-peptide levels increased with lipid infusion in control subjects but decreased in the FH+ group (+28 vs. -30%, respectively, P < 0.01). During the hyperglycemic clamp, lipid infusion enhanced the insulin secretion rate (ISR) in control subjects but decreased it in the FH+ group (first phase: +75 vs. -60%, P < 0.001; second phase: +25 vs. -35%, P < 0.04). When the ISR was adjusted for insulin resistance (ISRRd = ISR / [1/Rd], where Rd is the rate of insulin-stimulated glucose disposal), the inadequate beta-cell response in the FH+ group was even more evident. Although ISRRd was not different between the two groups before lipid infusion, in the FH+ group, lipid infusion reduced first- and second-phase ISR(Rd) to 25 and 42% of that in control subjects, respectively (both P < 0.001 vs. control subjects). Lipid infusion in the FH+ group (but not in control subjects) also caused severe hepatic insulin resistance with an increase in basal endogenous glucose production (EGP), despite an elevation in fasting insulin levels, and impaired suppression of EGP to insulin. In summary, in individuals who are genetically predisposed to type 2 diabetes, a sustained physiological increase in plasma FFA impairs insulin secretion in response to mixed meals and to intravenous glucose, suggesting that in subjects at high risk of developing type 2 diabetes, beta-cell lipotoxicity may play an important role in the progression from normal glucose tolerance to overt hyperglycemia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14514628     DOI: 10.2337/diabetes.52.10.2461

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  152 in total

Review 1.  β-Arrestins: multifunctional signaling adaptors in type 2 diabetes.

Authors:  Xiaotao Feng; Wenjian Wang; Jibo Liu; Yi Liu
Journal:  Mol Biol Rep       Date:  2010-11-18       Impact factor: 2.316

2.  Exogenous insulin enhances glucose-stimulated insulin response in healthy humans independent of changes in free fatty acids.

Authors:  Ximena Lopez; Aaron Cypess; Raquel Manning; Sheila O'Shea; Rohit N Kulkarni; Allison B Goldfine
Journal:  J Clin Endocrinol Metab       Date:  2011-09-28       Impact factor: 5.958

3.  Report from IPITA-TTS Opinion Leaders Meeting on the Future of β-Cell Replacement.

Authors:  Stephen T Bartlett; James F Markmann; Paul Johnson; Olle Korsgren; Bernhard J Hering; David Scharp; Thomas W H Kay; Jonathan Bromberg; Jon S Odorico; Gordon C Weir; Nancy Bridges; Raja Kandaswamy; Peter Stock; Peter Friend; Mitsukazu Gotoh; David K C Cooper; Chung-Gyu Park; Phillip OʼConnell; Cherie Stabler; Shinichi Matsumoto; Barbara Ludwig; Pratik Choudhary; Boris Kovatchev; Michael R Rickels; Megan Sykes; Kathryn Wood; Kristy Kraemer; Albert Hwa; Edward Stanley; Camillo Ricordi; Mark Zimmerman; Julia Greenstein; Eduard Montanya; Timo Otonkoski
Journal:  Transplantation       Date:  2016-02       Impact factor: 4.939

Review 4.  Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors.

Authors:  Ralph A DeFronzo; W Brian Reeves; Alaa S Awad
Journal:  Nat Rev Nephrol       Date:  2021-02-05       Impact factor: 28.314

5.  Effects of acute NEFA manipulation on incretin-induced insulin secretion in participants with and without type 2 diabetes.

Authors:  Brenno Astiarraga; Valéria B Chueire; Aglécio L Souza; Ricardo Pereira-Moreira; Sarah Monte Alegre; Andrea Natali; Andrea Tura; Andrea Mari; Ele Ferrannini; Elza Muscelli
Journal:  Diabetologia       Date:  2018-05-07       Impact factor: 10.122

Review 6.  Current status of the E23K Kir6.2 polymorphism: implications for type-2 diabetes.

Authors:  Michael J Riedel; Diana C Steckley; Peter E Light
Journal:  Hum Genet       Date:  2004-11-23       Impact factor: 4.132

7.  β-Cell dysfunction is associated with metabolic syndrome severity in adults.

Authors:  Steven K Malin; Stephen Finnegan; Ciaran E Fealy; Julianne Filion; Michael B Rocco; John P Kirwan
Journal:  Metab Syndr Relat Disord       Date:  2013-11-27       Impact factor: 1.894

Review 8.  Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor.

Authors:  Ralph A DeFronzo
Journal:  Diabetes Obes Metab       Date:  2017-06-07       Impact factor: 6.577

9.  Determinants of glucose tolerance in impaired glucose tolerance at baseline in the Actos Now for Prevention of Diabetes (ACT NOW) study.

Authors:  R A DeFronzo; M A Banerji; G A Bray; T A Buchanan; S Clement; R R Henry; A E Kitabchi; S Mudaliar; N Musi; R Ratner; P Reaven; D C Schwenke; F D Stentz; D Tripathy
Journal:  Diabetologia       Date:  2009-12-10       Impact factor: 10.122

10.  Twenty-four hour insulin secretion and beta cell NEFA oxidation in type 2 diabetic, morbidly obese patients before and after bariatric surgery.

Authors:  S Salinari; A Bertuzzi; A Iaconelli; M Manco; G Mingrone
Journal:  Diabetologia       Date:  2008-05-06       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.